摘要
【目的】探讨利拉鲁肽治疗血糖控制不佳的肥胖型2型糖尿病（T2DM）患者的疗效。【方法】选择40例血糖控制不佳的肥胖型T2DM患者，随机均分为两组，观察组采用利拉鲁肽治疗，对照组采用甘精胰岛素治疗，均治疗12周，比较两组患者治疗前后的体质量指数（BMI）、空腹血糖（FPG）、餐后2h血糖（2hPG）、糖化血红蛋白（HbA1c）、低密度脂蛋白（LDL）、甘油三脂（TG）、总胆固醇（TC）等指标变化。【结果】观察组治疗后体质量、BMI、FPG、2hPG、HbA1C及LDL、TG、TC较治疗前明显降低，对照组FPG、2hPG、HbA1C较治疗前明显下降（P〈0．05），差异有统计学意义（P〈0．05），但对照组患者体质量、BMI及LDL、TG、TC较治疗前比较差异无统计学意义（P〉0．05）。观察组较对照组FPG、2hPG、HbA1C下降明显（P〈0．05），差异有统计学意义（P〈0．05），而体质量、BMI及LDL、TG、TC比较均无统计学意义（P〉0．05）。【结论】利拉鲁肽可有效控制肥胖型T2DM患者血糖、调节血脂，并减轻体重，值得临床推广应用。
[Objective]To investigate effects of Liragtutide on obesity type 2 diabetic patients with poor blood glucose control.[MethodslFourty patients of obesity type 2 diabetic mellitus （T2DM） were chosen whose blood glucose were not well controlled, and randomly divided into the experimental group （liraglutide） and the control group （Insulin gtargine）. Both of them were given therapy for 12 weeks. The following index changes of the two groups were compared before and after medication ： body mass index（BMI）, fasting plasna glucose （FPG）. postprandial blood glucose（PBG）, hemoglobin Alc（ HbA1c）. low density lipoprotein （LDL）. triglyceride （ TG）. total cholesterol （TC） changes.[ResultslAfter treatment, the index of body weight, BMI, FPG, 2hPG, HbAlc , LDL, TG and TC of the observation group decreased significantly compared with those before treatment, and the FPG, 2hPG, HbAlc of the control group compared with those before treatment were also significantly decreased （ P〈 0.05）, the difference is statistically significant （ P〈0.05）.[Conclusion]Liraglutide for obesity type 2 diabetic patients can effectively control blood glucose, blood lipid and lose body mass, it is worthy of clinical application.
出处
《医学临床研究》
CAS
2015年第9期1728-1729,1732,共3页
Journal of Clinical Research
